<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101525337</journal-id>
<journal-id journal-id-type="pubmed-jr-id">37346</journal-id>
<journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id>
<journal-title-group>
<journal-title>ACS chemical neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1948-7193</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29792024</article-id>
<article-id pub-id-type="pmc">6192262</article-id>
<article-id pub-id-type="doi">10.1021/acschemneuro.8b00200</article-id>
<article-id pub-id-type="manuscript">NIHMS990846</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Joffe</surname>
<given-names>Max E.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6748-886X</contrib-id>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="aff" rid="A3">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Centanni</surname>
<given-names>Samuel W.</given-names>
</name>
<xref ref-type="aff" rid="A3">§</xref>
<xref ref-type="aff" rid="A4">ǁ</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaramillo</surname>
<given-names>Anel A.</given-names>
</name>
<xref ref-type="aff" rid="A3">§</xref>
<xref ref-type="aff" rid="A4">ǁ</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winder</surname>
<given-names>Danny G.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A3">§</xref>
<xref ref-type="aff" rid="A4">ǁ</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
<xref ref-type="corresp" rid="CR2">*</xref>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="aff" rid="A3">§</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>†</label>Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-0697, United States</aff>
<aff id="A2"><label>‡</label>Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232-0697, United States</aff>
<aff id="A3"><label>§</label>Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, Tennessee 37232-0697, United States</aff>
<aff id="A4"><label>ǁ</label>Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee 37212, United States</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Author Contributions</p>
<p id="P2">S.W.C. and A.A.J. contributed equally to this work. D.G.W. and P.J.C. contributed equally to this work. M.E.J. conceived the review. S.W.C. and A.A.J. composed the sections on interoception, binge/intoxication, and withdrawal. M.E.J. composed all other sections. M.E.J., S.W.C., A.A.J., D.G.W., and P.J.C. critically reviewed the document, tables, and figures.</p>
</fn>
<corresp id="CR1"><label>*</label><bold>Corresponding Authors:</bold> Department of Pharmacology, Vanderbilt University, 12475EMRB4, Nashville, TN 37232-0697. <email>max.joffe@vanderbilt.edu</email>. Telephone: (615) 322-6730. Fax: (615) 343-3088.</corresp>
<corresp id="CR2"><label>*</label>Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, 1205 Light Hall, Nashville, TN 37232-0697. <email>jeff.conn@vanderbilt.edu</email>. Telephone: (615) 936-2478. Fax: (615) 343-3088.</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P47">The authors declare the following competing financial interest(s): P.J.C. has been funded by the National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, the Michael J. Fox Foundation, the Dystonia Medical Research Foundation, the CHDI Foundation, and the Thome Memorial Foundation. Over the past three years, he has served on the Scientific Advisory Boards for the Michael J. Fox Foundation, the Stanley Center for Psychiatric Research Broad Institute, Karuna Pharmaceuticals, the Lieber Institute for Brain Development, Clinical Mechanism and Proof of Concept Consortium, and the Neurobiology Foundation for Schizophrenia and Bipolar Disorder. P.J.C. is an inventor on patents that protect different classes of mGlu receptor allosteric modulators. M.E.J., S.W.C., A.A.J., and D.G.W. declare no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>19</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>9</month>
<year>2019</year>
</pub-date>
<volume>9</volume>
<issue>9</issue>
<fpage>2188</fpage>
<lpage>2204</lpage>
<!--elocation-id from pubmed: 10.1021/acschemneuro.8b00200-->
<abstract id="ABS1">
<p id="P3">Developing efficacious treatments for alcohol use disorder (AUD) has proven difficult. The insidious nature of the disease necessitates a deep understanding of its underlying biology as well as innovative approaches to ameliorate ethanol-related patho-physiology. Excessive ethanol seeking and relapse are generated by long-term changes to membrane properties, synaptic physiology, and plasticity throughout the limbic system and associated brain structures. Each of these factors can be modulated by metabotropic glutamate (mGlu) receptors, a diverse set of G protein-coupled receptors highly expressed throughout the central nervous system. Here, we discuss how different components of the mGlu receptor family modulate neurotransmission in the limbic system and other brain regions involved in AUD etiology. We then describe how these processes are dysregulated following ethanol exposure and speculate about how mGlu receptor modulation might restore such pathophysiological changes. To that end, we detail the current understanding of the behavioral pharmacology of mGlu receptor-directed drug-like molecules in animal models of AUD. Together, this review highlights the prominent position of the mGlu receptor system in the pathophysiology of AUD and provides encouragement that several classes of mGlu receptor modulators may be translated as viable treatment options.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphical abstract</title>
<p id="P110">
<graphic orientation="portrait" position="anchor" xlink:href="nihms-990846-f0001.jpg"></graphic>
</p>
</abstract>
<kwd-group>
<kwd>Alcohol use disorder</kwd>
<kwd>metabotropic glutamate receptor</kwd>
<kwd>synaptic plasticity</kwd>
<kwd>prefrontal cortex</kwd>
<kwd>nucleus accumbens</kwd>
<kwd>bed nucleus of the stria terminalis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>